Shiv Kumar Viswanathan

Shiv Kumar Viswanathan

Auto-generated profile, based on publicly available information

Shiv Kumar Viswanathan

Heart, Lung and Vascular Institute, Department of Internal Medicine, University of Cincinnati, Cincinnati, Ohio

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 November 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SVShiv Kumar Viswanathan
Shiv Kumar Viswanathan
HSHeather K Sanders
Heather K Sanders
JMJames McNamara
James McNamara
AJAravindakshan Jagadeesan
Aravindakshan Jagadeesan
AJArshad Jahangir
Arshad Jahangir
Sakthivel SadayappanSakthivel Sadayappan
Sakthivel Sadayappan
Over 1,500 gene mutations are known to cause hypertrophic cardiomyopathy (HCM). Previous studies suggest that cardiac β-myosin heavy chain (MYH7) gene mutations are commonly associated with a more severe phenotype, compared to cardiac myosin binding protein-C (MYBPC3) gene mutations with milder phenotype, incomplete penetrance and later age of onset. Compound mutations can worsen the phenotype. This study aimed to validate these comparative differences in a large cohort of individuals and families with HCM. We performed genome-phenome correlation among 80 symptomatic HCM patients, 35 asymptomatic carriers and 35 non-carriers, using an 18-gene clinical diagnostic HCM panel. A total of 125 mutations were identified in 14 genes. MYBPC3 and MYH7 mutations contributed to 50.0% and 24.4% of the HCM patients, respectively, suggesting that MYBPC3 mutations were the most frequent cause of HCM in our cohort. Double mutations were found in only nine HCM patients (7.8%) who were phenotypically indistinguishable from single-mutation carriers. Comparisons of clinical parameters of MYBPC3 and MYH7 mutants were not statistically significant, but asymptomatic carriers had high left ventricular ejection fraction and diastolic dysfunction when compared to non-carriers. The presence of double mutations increases the risk for symptomatic HCM with no change in severity, as determined in this study subset. The pathologic effects of MYBPC3 and MYH7 were found to be independent of gene mutation location. Furthermore, HCM pathology is independent of protein domain disruption in both MYBPC3 and MYH7. These data provide evidence that MYBPC3 mutations constitute the preeminent cause of HCM and that they are phenotypically indistinguishable from HCM caused by MYH7 mutations.

1 October 2007 in European Journal of Pharmacology
Verified
Journal Article
Closed access
ASAnantha Vijay R Santhanam
Anantha Vijay R Santhanam
SVShivkumar Viswanathan
Shivkumar Viswanathan
MDMadhu Dikshit
Madhu Dikshit

1 June 2018 in JAMA Cardiology
Verified
Journal Article
Closed access
PDF file
SVShiv Kumar Viswanathan
Shiv Kumar Viswanathan
MPMegan J. Puckelwartz
Megan J. Puckelwartz
AMAshish Mehta
Ashish Mehta
CRChrishan J Ramachandra
Chrishan J Ramachandra
AJAravindakshan Jagadeesan
Aravindakshan Jagadeesan
Sakthivel SadayappanSakthivel Sadayappan
Sakthivel Sadayappan
Importance The genetic variantMYBPC3Δ25bpoccurs in 4% of South Asian descendants, with an estimated 100 million carriers worldwide.MYBPC3 Δ25bphas been linked to cardiomyopathy and heart failure. However, the high prevalence ofMYBPC3Δ25bpsuggests that other stressors act in concert withMYBPC3Δ25bp. Objective To determine whether there are additional genetic factors that contribute to the cardiomyopathic expression ofMYBPC3Δ25bp. Design, Setting, andParticipants South Asian individuals living in the United States were screened forMYBPC3Δ25bp, and a subgroup was clinically evaluated using electrocardiograms and echocardiograms at Loyola University, Chicago, Illinois, between January 2015 and July 2016. Main Outcomes and Measures Next-generation sequencing of 174 cardiovascular disease genes was applied to identify additional modifying gene mutations and correlate genotype-phenotype parameters. Cardiomyocytes derived from human-induced pluripotent stem cells were established and examined to assess the role ofMYBPC3Δ25bp. Results In this genotype-phenotype study, individuals of South Asian descent living in the United States from both sexes (36.23% female) with a mean population age of 48.92 years (range, 18-84 years) were recruited. Genetic screening of 2401 US South Asian individuals found anMYBPC3Δ25bpcarrier frequency of 6%. A higher frequency of missenseTTNvariation was found inMYBPC3Δ25bpcarriers compared with noncarriers, identifying distinct genetic backgrounds within theMYBPC3Δ25bpcarrier group. Strikingly, 9.6% ofMYBPC3Δ25bpcarriers also had a novelMYBPC3variant, D389V. Family studies documented D389V was in tandem on the same allele asMYBPC3Δ25bp, and D389V was only seen in the presence ofMYBPC3Δ25bp. In contrast toMYBPC3Δ25bp,MYBPC3Δ25bp/D389Vwas associated with hyperdynamic left ventricular performance (mean [SEM] left ventricular ejection fraction, 66.7 [0.7%]; left ventricular fractional shortening, 36.6 [0.6%];P < .03) and stem cell–derived cardiomyocytes exhibited cellular hypertrophy with abnormal Ca2+transients. Conclusions and Relevance MYBPC3Δ25bp/D389Vis associated with hyperdynamic features, which are an early finding in hypertrophic cardiomyopathy and thought to reflect an unfavorable energetic state. These findings support that a subset ofMYBPC3Δ25bpcarriers, those with D389V, account for the increased risk attributed toMYBPC3Δ25bp.

1 May 2007 in Journal of Molecular and Cellular Cardiology
Verified
Journal Article
Closed access
SVS. Viswanathan
S. Viswanathan
JBJ.B.E. Burch
J.B.E. Burch
GFGlenn Fishman
Glenn Fishman
IMI.P. Moskowitz
I.P. Moskowitz
DBD.W. Benson
D.W. Benson

1 September 2017 in Cytotherapy
Verified
Journal Article
Closed access
FUFabrizia Urbinati
Fabrizia Urbinati
JWJennifer Wherley
Jennifer Wherley
SGSabine Geiger
Sabine Geiger
BFBeatriz Campo Fernandez
Beatriz Campo Fernandez
MKMichael L. Kaufman
Michael L. Kaufman
DKDonald B. Kohn
Donald B. Kohn

28 October 2016 in Frontiers in Physiology
Verified
Journal Article
Open access
JKJessica Kraker
Jessica Kraker
SVShiv Kumar Viswanathan
Shiv Kumar Viswanathan
RKRalph Knöll
Ralph Knöll
Sakthivel SadayappanSakthivel Sadayappan
Sakthivel Sadayappan
The South Asian population, numbered at 1.8 billion, is estimated to comprise around 20% of the global population and 1% of the American population, and has one of the highest rates of cardiovascular disease. While South Asians show increased classical risk factors for developing heart failure, the role of population-specific genetic risk factors has not yet been examined for this group. Hypertrophic cardiomyopathy (HCM) is one of the major cardiac genetic disorders among South Asians, leading to contractile dysfunction, heart failure, and sudden cardiac death. This disease displays autosomal dominant inheritance, and it is associated with a large number of variants in both sarcomeric and non-sarcomeric proteins. South Asians, a population with large ethnic diversity, potentially carries region-specific polymorphisms. There is high variability in disease penetrance and phenotypic expression of variants associated with HCM. Thus, extensive studies are required to decipher pathogenicity and the physiological mechanisms of these variants, as well as the contribution of modifier genes and environmental factors to disease phenotypes. Conducting genotype-phenotype correlation studies will lead to improved understanding of HCM and, consequently, improved treatment options for this high-risk population. The objective of this review is to report the history of cardiovascular disease and HCM in South Asians, present previously published pathogenic variants, and introduce current efforts to study HCM using induced pluripotent stem cell-derived cardiomyocytes, next-generation sequencing, and gene editing technologies. The authors ultimately hope that this review will stimulate further research, drive novel discoveries, and contribute to the development of personalized medicine with the aim of expanding therapeutic strategies for HCM.